Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;28(5):831-839.
doi: 10.1158/1078-0432.CCR-21-3238.

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K Choueiri  1 , Laurence Albiges  2 , Michael B Atkins  3 , Ziad Bakouny  1 , Gennady Bratslavsky  4 , David A Braun  1 , Naomi B Haas  5 , John B A G Haanen  6 , A Ari Hakimi  7 , Michael A S Jewett  8 , Eric Jonasch  9 , William G Kaelin  1 , Payal Kapur  10 , Chris Labaki  1 , Bryan Lewis  11 , David F McDermott  12 , Sumanta K Pal  13 , Kevin Pels  1 , Susan Poteat  11 , Thomas Powles  14 , W Kimryn Rathmell  15 , Brian I Rini  15 , Sabina Signoretti  16 , Nizar M Tannir  9 , Robert G Uzzo  17 , Hans J Hammers  18
Affiliations

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K Choueiri et al. Clin Cancer Res. .

Abstract

The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Subject areas covered in the different sessions at the Kidney Cancer Research Summit (KCRS) 2020.
Abbreviations: BCR: B-cell receptor ; chRCC: chromophobe renal cell carcinoma ; GGT1: gamma-glutamyl transferase 1 ; Pfn1: profilin 1 ; pRCC: papillary renal cell carcinoma ; TLR: toll-like receptor ; tRCC: translocation renal cell carcinoma
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. Wiley; 2021;71:7–33. - PubMed
    1. Choueiri TK, Kaelin WG. Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat. Med Nature Research; 2020. page 1519–30. - PubMed
    1. Albiges L, Flippot R, Rioux-Leclercq N, Choueiri TK. Non–Clear Cell Renal Cell Carcinomas: From Shadow to Light. J Clin Oncol. 2018;36:3624–31. - PubMed
    1. Motzer RJ, Hutson TE, Tomczack P, Michaelson D, Bukowksi RM, Rixe O, et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2005;687–96. - PubMed
    1. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer. N Engl J Med. 2003;687–96. - PMC - PubMed